Celcuity Past Earnings Performance
Past criteria checks 0/6
Celcuity's earnings have been declining at an average annual rate of -46.5%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-46.5%
Earnings growth rate
-25.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -62.8% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Celcuity: Breast Cancer Drug Developer With Upcoming Catalysts
Nov 06Is Celcuity (NASDAQ:CELC) Using Too Much Debt?
Aug 31
Celcuity: Flying A Phase 3 Trial Right Under Your Nose
Jul 05Does Celcuity (NASDAQ:CELC) Have A Healthy Balance Sheet?
May 08Is Celcuity (NASDAQ:CELC) Using Too Much Debt?
Jul 04Is Celcuity (NASDAQ:CELC) A Risky Investment?
Sep 13Celcuity rises after hours on FDA Breakthrough Therapy nod for its breast cancer treatment
Jul 18Is Celcuity (NASDAQ:CELC) A Risky Investment?
Jan 27Health Check: How Prudently Does Celcuity (NASDAQ:CELC) Use Debt?
Sep 21Celcuity: Nipping The Oncogenic Bud
Jul 08What You Need To Know About Celcuity Inc.'s (NASDAQ:CELC) Investor Composition
Mar 14We're Hopeful That Celcuity (NASDAQ:CELC) Will Use Its Cash Wisely
Jan 20Celcuity inks clinical trial pact with Massachusetts General Hospital and Puma Technologies
Dec 23Could The Celcuity Inc. (NASDAQ:CELC) Ownership Structure Tell Us Something Useful?
Nov 29Celcuity EPS beats by $0.03
Nov 09Revenue & Expenses Breakdown
How Celcuity makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -94 | 8 | 88 |
| 30 Jun 24 | 0 | -83 | 7 | 78 |
| 31 Mar 24 | 0 | -73 | 7 | 70 |
| 31 Dec 23 | 0 | -64 | 6 | 60 |
| 30 Sep 23 | 0 | -57 | 5 | 53 |
| 30 Jun 23 | 0 | -49 | 5 | 45 |
| 31 Mar 23 | 0 | -45 | 5 | 40 |
| 31 Dec 22 | 0 | -41 | 4 | 35 |
| 30 Sep 22 | 0 | -36 | 4 | 30 |
| 30 Jun 22 | 0 | -31 | 4 | 25 |
| 31 Mar 22 | 0 | -35 | 3 | 30 |
| 31 Dec 21 | 0 | -30 | 3 | 25 |
| 30 Sep 21 | 0 | -25 | 2 | 22 |
| 30 Jun 21 | 0 | -22 | 2 | 19 |
| 31 Mar 21 | 0 | -10 | 2 | 8 |
| 31 Dec 20 | 0 | -9 | 2 | 7 |
| 30 Sep 20 | 0 | -9 | 2 | 7 |
| 30 Jun 20 | 0 | -8 | 2 | 7 |
| 31 Mar 20 | 0 | -8 | 2 | 6 |
| 31 Dec 19 | 0 | -7 | 2 | 6 |
| 30 Sep 19 | 0 | -7 | 1 | 6 |
| 30 Jun 19 | 0 | -7 | 1 | 6 |
| 31 Mar 19 | 0 | -7 | 1 | 6 |
| 31 Dec 18 | 0 | -7 | 2 | 6 |
| 30 Sep 18 | 0 | -7 | 2 | 6 |
| 30 Jun 18 | 0 | -7 | 2 | 6 |
| 31 Mar 18 | 0 | -7 | 1 | 6 |
| 31 Dec 17 | 0 | -6 | 1 | 5 |
| 30 Sep 17 | 0 | -5 | 1 | 4 |
| 30 Jun 17 | 0 | -5 | 1 | 4 |
| 31 Mar 17 | 0 | -4 | 0 | 3 |
| 31 Dec 16 | 0 | -3 | 0 | 3 |
Quality Earnings: CELC is currently unprofitable.
Growing Profit Margin: CELC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CELC is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.
Accelerating Growth: Unable to compare CELC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CELC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CELC has a negative Return on Equity (-62.77%), as it is currently unprofitable.